Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan’s Diet Enacts Bill to Establish Pandemic Response Agency
Japan’s Diet on April 21 enacted a bill to create an infectious disease crisis management agency, which will serve as the command tower for pandemic responses. The agency is slated for launch as early as September 1. The establishment of…
To read the full story
Related Article
- Japan Launches Agency for Infectious Disease Crisis Management
September 4, 2023
- Shunichi Kuryu to Take Helm at New Infectious Disease Agency
August 28, 2023
- Japan’s Pandemic Response Agency Officially Set to Launch on September 1
August 10, 2023
- Japan Diet Ends Ordinary Session, All 7 MHLW-Submitted Bills Enacted
June 22, 2023
- Pandemic Response Agency to Be Set Up as Early as September: Minister Goto
April 12, 2023
- Japan Cabinet OKs Bill to Create Pandemic Response Agency
February 8, 2023
- MHLW Planning to Submit 6 Bills in Ordinary Diet Session, “Japan CDC” Plan Included
January 13, 2023
- Japan Eyes FY2023 Launch of Pandemic Response Agency
August 29, 2022
- Deliberations Underway for Transfer of Some MHLW Functions to Boost Pandemic Responses: Vice Health Minister
August 10, 2022
- Govt Officially OKs Launch of Pandemic Response Agency, Japan CDC
June 20, 2022
- Kishida Officially Unveils Plan to Form Pandemic Response Agency, Japan CDC
June 16, 2022
- Japan to Launch New Agency for Pandemic Responses, Eyes MHLW Rejig
June 15, 2022
REGULATORY
- Japan Panel Backs Daiichi’s MMR Vaccine, Haihe’s PI3Kα Inhibitor, MSD’s HIV Med
March 3, 2026
- MHLW Revises Guidance on Pediatric Development Plans under Amended PMD Act
March 3, 2026
- MHLW Details New Operational Rules for Conditional Approvals from May
March 3, 2026
- MHLW Seeks Sponsors to Develop 8 “Drug-Loss” Products
March 2, 2026
- WG Members Urge Domestic Biologic Production as National Growth Strategy
March 2, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…